AHCL
Anlon Healthcare Limited (ahcl) Q4 FY26: Revenue Up 43%, Ebitda Surges 48%
Anlon Healthcare Limited (AHCL) reports 43% revenue growth and 48% EBITDA surge in Q4 FY26, driven by strategic acquisitions and robust R&D.
Anlon Healthcare Limited (AHCL) has reported a remarkable financial performance for Q4 and FY26, showcasing a 43% revenue growth and a 48% increase in EBITDA. The company’s consolidated total income rose to ₹172.22 Crores, marking a significant year in its growth journey. This strong performance was driven by strategic acquisitions, robust R&D execution, and capacity expansion initiatives.
Strategic Acquisitions
The company completed the acquisition of Bizotic Lifescience, which has now become a subsidiary of AHCL, thereby strengthening its manufacturing platform and growth capabilities. Additionally, Apiqo Organics has continued to enhance backward integration capabilities and supply-chain efficiency across pharmaceutical intermediates and specialty chemical products.
Operational Efficiency
AHCL’s focus on expanding its presence across pharmaceutical, nutraceutical, veterinary, and personal care sectors has paid off. The company’s disciplined execution across key business verticals and operational efficiencies have been pivotal in achieving these results. The management is optimistic about capitalizing on growing opportunities in APIs and pharmaceutical intermediates.
Future Outlook
Mr. Punitkumar Rasadia, Chairman & Managing Director of Anlon Healthcare Limited, expressed confidence in the company’s future growth trajectory. The company aims to deliver approximately 30% revenue CAGR over the next three years, while maintaining EBITDA margins in the range of 25-30%. With its expanded manufacturing platform, regulatory capabilities, diversified product portfolio, and strategic acquisitions, AHCL is well-positioned for sustained growth.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Anlon Healthcare Limited
Anlon Healthcare Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Anlon falls 87.2% over three months and has not found a floor yet. Margins at 20.4% are impressive but need to be sustained — any compression would be a red flag. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI stands at 20, well into oversold territory. Yet sellers still dominated on 13 of recent sessions versus 17 for buyers, so the pressure has not fully lifted. Revenue grows at 28.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Anlon Healthcare Limited.
AHCL
Anlon Healthcare Limited (ahcl) Q1 FY27: Topline Growth Up 163%, Ebitda Up 150%
Anlon Healthcare Limited (AHCL) reports 163% topline growth, 150% EBITDA growth and 133% PAT growth in Q1 FY27, strengthening its integrated pharmaceutical p.
Anlon Healthcare Limited (AHCL) announced its unaudited financial results for Q1 FY27, showcasing a remarkable 163.02% year-on-year growth in consolidated total income to ₹87.62 crore, 150.14% growth in EBITDA to ₹15.65 crore, and 133.13% growth in Profit After Tax (PAT) to ₹8.28 crore. This performance highlights the strength of AHCL’s diversified pharmaceutical portfolio, continued customer confidence, and the positive contribution from strategic acquisitions.
Key Developments
During the quarter, AHCL strengthened its integrated pharmaceutical platform through the acquisition of a 63.98% stake in Remember India Health Links Pvt. Ltd. for ₹5.38 crore, completed on May 8, 2026, making it a subsidiary. The company expanded into the Finished Dosage Formulations (FDF) segment, broadening its product portfolio with access to over 30 formulation dossiers. AHCL also enhanced market presence by expanding into B2B APIs, domestic retail, and hospital markets.
Operational Synergies
AHCL improved operational synergies through the integration of manufacturing and quality control processes, driving enhanced operational efficiencies and strengthening long-term scalability. Mr. Punitkumar Rasadia, Chairman & Managing Director of AHCL, commented on the company’s strong results, emphasizing the resilience of the business model and focus on operational excellence.
Looking ahead, AHCL remains focused on expanding its presence in regulated markets, scaling its CDMO business, and leveraging its integrated pharmaceutical platform to drive sustainable growth. With enhanced manufacturing capabilities, a diversified product portfolio, and strategic acquisitions, AHCL is confident of achieving its long-term guidance of approximately 30% revenue CAGR over the next three years, while maintaining EBITDA margins in the range of 25%-30%.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Anlon Healthcare Limited
Anlon Healthcare Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Anlon posts a 9.2% three-month gain, but softens in the last few weeks. The PEG of 0.34 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 15.1% and profits at 69.8% CAGR. That is strong double-digit growth on both counts. The stock gives back 9.2% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 15.1% and profits at 69.8%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Anlon Healthcare Limited.
-
Industrials3 days agoReliance Industrial Infrastructure Limited (riil) Reports Q2 Fy26-27 Results: Income Down, Profit Margins Narrow
-
Financial Services3 days agoIcici Lombard General Insurance Company Limited Q2 Fy2027: Profit Soars by 27.5% Declares Interim Dividend of ₹7.00 Per Share
-
Auto Parts3 days agoCeat Limited Q2 FY27: Investor Presentation Highlights Road to Siberia Expansion
-
Healthcare2 days agoMankind Pharma Limited to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-generation CAR-T Therapies
-
Consumer Defensive3 days agoNiit Limited (NSE: Niitltd) Appoints Anish Sarkar as Chief Executive Officer
-
BAJAJCON3 days agoBajaj Consumer Care Limited (bajajcon) Q2 FY27: Strong Growth & Margin Momentum
-
ANGELONE2 days agoAngel One Limited (NSE: Angelone) Q2 FY27: Revenue and PAT Surge, Client Funding Book Hits ₹74.5 Bn
-
DSSL2 days agoDynacons Systems & Solutions Limited (dssl) Honoured with ‘spirit of Partnership’ Award at Motadata Amplify